BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Biotech Bay

  Google-Backed FLX Bio Scores $60M Financing

  New investors included GV and undisclosed investors.

  December 21, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  J&J Gets $30M Fine for Allegedly Restricting Access to Generic Versions of Its Pain Patch

  France’s competition authority finedJ&K $29.6M on Wednesday after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.

  December 21, 2017

   · 

  1 min read
• 

  Drug Development

  Celgene Crashed After Follicular Lymphoma Regimen Failed Phase III

  Celgene announced the Phase III results late Thursday and share prices dropped about 4 percent to $102.69 as of 9:30 this morning.

  December 21, 2017

   · 

  2 min read

   · 

  Alex Keown
• ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018

  Abivax announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

  December 21, 2017

   · 

  1 min read
• FDA

  EU Follows US and Approves Chugai’s ALK Inhibitor “Alecensa®" as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer

  Chugai Pharmaceutical Co., Ltd announced today that F. Hoffmann-La Roche Ltd. obtained approval from the European Commission, for Alecensa® as monotherapy indicated for “the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)”.

  December 21, 2017

   · 

  5 min read
• Business

  vTv Therapeutics Announces Licensing Agreement With Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTv’s GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories

  Under the terms of the agreement, vTv Therapeutics will run a Phase 2 Multi-Regional Clinical Trial (MRCT) including sites in the US and other regions in the Pacific Rim.

  December 21, 2017

   · 

  6 min read
• Business

  Denis DELVAL is Appointed CEO of LFB SA

  Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.

  December 21, 2017

   · 

  2 min read
• Policy

  Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing Under the FDA Animal Rule

  Soligenix announced today that biomarkers for ricin toxin vaccine testing have been successfully identified, facilitating potential approval under the FDA “Animal Rule”.

  December 21, 2017

   · 

  11 min read
• Policy

  NovaBay Pharmaceuticals Regains Compliance With NYSE American Continued Listing Standards

  NovaBay announces that it has regained compliance with NYSE American continued listing standards.

  December 21, 2017

   · 

  3 min read
• Pharm Country

  Pfizer Inc. Announces Pricing and Early Results of Its Tender Offer for Its 5.750 Per Cent. Notes Due 2021 and Related Solicitation of Consents

  Pfizer Inc. announced the pricing terms and the early tender results of its previously announced (i) offer to purchase for cash (the “Tender Offer”) any and all of its outstanding €2,000,000,000 5.750 per cent.

  December 21, 2017

   · 

  10 min read